|
1
|
Sramek M, Neradil J and Veselska R: Much
more than you expected: the non-DHFR-mediated effects of
methotrexate. Biochim Biophys Acta Gen Subj. 1861:499–503. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chan ESL and Cronstein BN: Molecular
action of methotrexate in inflammatory diseases. Arthritis Res.
4:266–273. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pathirana D, Ormerod AD, Saiag P, Smith C,
Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, et
al: European S3-guidelines on the systemic treatment of psoriasis
vulgaris. J Eur Acad Dermatol Venereol. 23:1–70. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Belgi G and Friedmann PS: Traditional
therapies: glucocorticoids, azathioprine, methotrexate,
hydroxyurea. Clin Exp Dermatol. 27:546–554. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bangert CA and Costner MI: Methotrexate in
dermatology. Dermatol Ther. 20:216–228. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Negrei C, Ginghina O, Caruntu C,
Burcea-Dragomiroiu GTA, Jinescu G and Boda D: Investigation
relevance of methotrexate polyglutamates in biological systems by
high performance liquid chromatography. Rev Chim. 66:766–768.
2015.
|
|
7
|
Strober BE and Menon K: Folate
supplementation during methotrexate therapy for patients with
psoriasis. J Am Acad Dermatol. 53:652–659. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zimmerman MC, Clemens DL, Duryee MJ,
Sarmiento C, Chiou A, Hunter CD, Tian J, Klassen LW, O'Dell JR,
Thiele GM, et al: Direct antioxidant properties of methotrexate:
inhibition of malondialdehyde-acetaldehyde-protein adduct formation
and superoxide scavenging. Redox Biol. 13:588–593. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Negrei C, Caruntu C, Ginghina O,
Burcea-Dragomiroiu GTA, Toderescu CD and Boda D: Qualitative and
quantitative determination of methotrexate polyglutamates in
erythrocytes by high performance liquid chromatography. Rev Chim.
66:607–610. 2015.
|
|
10
|
Caruntu C, Boda D, Dumitrascu G,
Constantin C and Neagu M: Proteomics focusing on immune markers in
psoriatic arthritis. Biomark Med. 9:513–528. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Batani A, Brănișteanu DE, Ilie MA, Boda D,
Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary
and microvascular parameters in psoriasis vulgaris using in vivo
reflectance confocal microscopy. Exp Ther Med. 15:1241–1246.
2018.PubMed/NCBI
|
|
12
|
Boda CBD, Negrei C and Nicolescu F:
Assessment of some oxidative stress parameters in methotrexate
treated psoriasis patients. Farmacia. 62:704–710. 2014.
|
|
13
|
Kremer JM: Toward a better understanding
of methotrexate. Arthritis Rheum. 50:1370–1382. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Newman M, Auerbach R, Feiner H, Holzman
RS, Shupack J, Migdal P, Culubret M, Camuto P and Tobias H: The
role of liver biopsies in psoriatic patients receiving long-term
methotrexate treatment. Improvement in liver abnormalities after
cessation of treatment. Arch Dermatol. 125:1218–1224. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roenigk HH Jr, Auerbach R, Maibach H,
Weinstein G and Lebwohl M: Methotrexate in psoriasis: Consensus
conference. J Am Acad Dermatol. 38:478–485. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu S, Papp KA, Lebwohl MG, Bagel J,
Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR,
Fiorentino DF, et al National Psoriasis Foundation Medical Board, :
Consensus guidelines for the management of plaque psoriasis. Arch
Dermatol. 148:95–102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kalb RE, Strober B, Weinstein G and
Lebwohl M: Methotrexate and psoriasis: 2009 National Psoriasis
Foundation Consensus Conference. J Am Acad Dermatol. 60:824–837.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Summary of Product Characteristics: Annex
I. https://www.ema.europa.eu/documents/product-information/nordimet-epar-product-information_en.pdf
|
|
19
|
Lim AYN, Gaffney K and Scott DGI:
Methotrexate-induced pancytopenia: Serious and under-reported? Our
experience of 25 cases in 5 years. Rheumatology (Oxford).
44:1051–1055. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Duhra P: Treatment of gastrointestinal
symptoms associated with methotrexate therapy for psoriasis. J Am
Acad Dermatol. 28:466–469. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Temprano KK, Bandlamudi R and Moore TL:
Antirheumatic drugs in pregnancy and lactation. Semin Arthritis
Rheum. 35:112–121. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Manna R, Verrecchia E, Diaco M, Montalto
M, Cammarota G and Gasbarrini G: Folic acid supplementation during
methotrexate treatment: Nonsense? Rheumatology (Oxford).
44:563–564. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Murphy R: Folic acid reduces the efficacy
of methotrexate. Nat Clin Pract Rheumatol. 2:42006. View Article : Google Scholar
|
|
24
|
Whittle SL and Hughes RA: Folate
supplementation and methotrexate treatment in rheumatoid arthritis:
a review. Rheumatology (Oxford). 43:267–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lopez-Olivo MA, Siddhanamatha HR, Shea B,
Tugwell P, Wells GA and Suarez-Almazor ME: Methotrexate for
treating rheumatoid arthritis. Cochrane Database Syst Rev.
10:CD0009572014.
|
|
26
|
Olteanu R, Zota A and Constantin M:
Biosimilars: an update on clinical trials (review of published and
ongoing studies). Acta Dermatovenerol Croat. 25:57–66.
2017.PubMed/NCBI
|
|
27
|
Rodica O, Constantin MM, Zota A, Dorobantu
DM, Constantin T, Serban ED, Balanescu P, Mihele D and Solovastru
LG: Original clinical experience and approach to treatment study
with interleukine 12/23 inhibitor in moderate-to-severe psoriasis
patients. Farmacia. 64:918–921. 2016.
|
|
28
|
Tian H and Cronstein BN: Understanding the
mechanisms of action of methotrexate: Implications for the
treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis.
65:168–173. 2007.PubMed/NCBI
|
|
29
|
Phillips DC, Woollard KJ and Griffiths HR:
The anti-inflammatory actions of methotrexate are critically
dependent upon the production of reactive oxygen species. Br J
Pharmacol. 138:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Annest NM, VanBeek MJ, Arpey CJ and
Whitaker DC: Intralesional methotrexate treatment for
keratoacanthoma tumors: a retrospective study and review of the
literature. J Am Acad Dermatol. 56:989–993. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoo MG and Kim IH: Intralesional
methotrexate for the treatment of keratoacanthoma: Retrospective
study and review of the korean literature. Ann Dermatol.
26:172–176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goebeler M, Lurz C, Kolve-Goebeler ME and
Bröcker EB: Pancytopenia after treatment of keratoacanthoma by
single lesional methotrexate infiltration. Arch Dermatol.
137:1104–1105. 2001.PubMed/NCBI
|
|
33
|
Cohen PR, Schulze KE and Nelson BR:
Pancytopenia after a single intradermal infiltration of
methotrexate. J Drugs Dermatol. 4:648–651. 2005.PubMed/NCBI
|
